Skip to Main Content
Mestag Therapeutics
Menu Button
  • About
    • Team
    • Partners and Collaborators
    • Investors
  • Science
    • Our Approach
    • Tertiary Lymphoid Structures
    • Publications
  • Pipeline
  • Life at Mestag
    • Our Culture
    • Team Mestag
    • Opportunities
  • News & Events
    • Press Releases
    • Events & Presentations
  • Contact
Lines
Hero

M300 Publications

Conditionally active, therapeutic lymphotoxin beta receptor (LTBR) agonist bispecific antibodies for induction of tertiary lymphoid structures in the treatment of solid tumors
April 29, 2024
Read More
Mestag Therapeutics
  • About
  • Science
  • Pipeline
  • Life at Mestag
  • News & Events
  • Contact
  • Privacy Policy
  • Twitter
  • LinkedIn